

RESEARCH

Open Access

Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in *Plasmodium falciparum*

Claire Le Manach¹, Christian Scheurer^{2,3}, Sibylle Sax^{2,3}, Sarah Schleiferböck^{2,3}, Diego Gonzalez Cabrera¹, Yassir Younis¹, Tanya Paquet¹, Leslie Street¹, Peter Smith⁴, Xavier C Ding⁵, David Waterson⁵, Michael J Witty⁵, Didier Leroy⁵, Kelly Chibale¹ and Sergio Wittlin^{2,3*}

Abstract

Background: Recent whole cell in vitro screening campaigns identified thousands of compounds that are active against asexual blood stages of *Plasmodium falciparum* at submicromolar concentrations. These hits have been made available to the public, providing many novel chemical starting points for anti-malarial drug discovery programmes. Knowing which of these hits are fast-acting compounds is of great interest. Firstly, a fast action will ensure rapid relief of symptoms for the patient. Secondly, by rapidly reducing the parasitaemia, this could minimize the occurrence of mutations leading to new drug resistance mechanisms.

An in vitro assay that provides information about the speed of action of test compounds has been developed by researchers at GlaxoSmithKline (GSK) in Spain. This assay also provides an in vitro measure for the ratio between parasitaemia at the onset of drug treatment and after one intra-erythrocytic cycle (parasite reduction ratio, PRR). Both parameters are needed to determine in vitro killing rates of anti-malarial compounds. A drawback of the killing rate assay is that it takes a month to obtain first results.

Methods: The approach described in the present study is focused only on the speed of action of anti-malarials. This has the advantage that initial results can be achieved within 4–7 working days, which helps to distinguish between fast and slow-acting compounds relatively quickly. It is expected that this new assay can be used as a filter in the early drug discovery phase, which will reduce the number of compounds progressing to secondary, more time-consuming assays like the killing rate assay.

Results: The speed of action of a selection of seven anti-malarial compounds was measured with two independent experimental procedures using modifications of the standard [³H]hypoxanthine incorporation assay. Depending on the outcome of both assays, the tested compounds were classified as either fast or non-fast-acting.

Conclusion: The results obtained for the anti-malarials chloroquine, artesunate, atovaquone, and pyrimethamine are consistent with previous observations, suggesting the methodology is a valid way to rapidly identify fast-acting anti-malarial compounds. Another advantage of the approach is its ability to discriminate between static or cidal compound effects.

Keywords: *Plasmodium falciparum*, Speed of action, Stage-specificity

* Correspondence: sergio.wittlin@unibas.ch

²Parasite Chemotherapy Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland

³University of Basel, Basel CH-4003, Switzerland

Full list of author information is available at the end of the article

Background

Malaria is one of the most devastating infectious diseases in the world and is responsible for an estimated 544,700-904,000 deaths each year [1]. It annually affects hundreds of millions of people, principally in sub-Saharan Africa, Asia and South America, with young children and pregnant women being particularly at risk. The fight against malaria remains a constant challenge as parasites manage to adapt and develop resistance mechanisms, making them less sensitive to the latest drugs. A critical example of the latter is the observed delay in parasite clearance time following artemisinin-based combination therapy (ACT) in Southeast Asia [2,3]. Since ACT has been adopted worldwide as first-line treatment, the rise of resistance to these drugs could lead to a malaria resurgence. The development of new anti-malarial agents is thus urgently needed to counter the spread of drug-resistant malaria.

The last few years have seen the development of innovative high-throughput screening that allowed testing of millions of compounds from diverse libraries against whole parasites [4]. GlaxoSmithKline [5] (GSK), Novartis [6] and St Jude's [7] have screened their collections against the erythrocytic stages of *Plasmodium falciparum*. More than 20,000 hits that inhibit or kill the parasite at a concentration of less than 1 μ M were identified. As a result, an explosion of numbers of active new chemotypes that can potentially be developed as anti-malarial drugs have been reported [8-10].

However, one of the main current challenges is to be able to assess the potential of these chemotypes early in the drug discovery process. New drugs should ideally have a rapid onset of action to relieve patient symptoms as fast as possible and so that a minimal number of parasites survive after exposure to the drug, thereby minimizing the resistance selection risk [9-11]. In this prospect, researchers at GSK in Spain have developed a killing rate assay that allows measuring the effect of a compound on parasite viability over time by determining its killing rate and speed of action [12]. A drawback of this method is that first results cannot be expected before four weeks.

In order to get a quicker evaluation of the speed of action of a compound and to solve the lack of filters in the early stage of the drug discovery testing cascade, a method based on modifications to the standard [3 H]hypoxanthine

incorporation assay was developed. The first results were achieved within a week.

The method was validated with the anti-malarial standards chloroquine, artesunate, atovaquone, and pyrimethamine and was also used to determine the speed of action of three novel compounds (**1** [13], **2** [14] and **3**) (Figure 1), derived from different series identified during screening of Biofocus libraries [15].

Methods

Chemicals and materials

Chloroquine (MW: 516), artesunate (MW: 384), atovaquone (MW: 367) and pyrimethamine (MW: 249) were obtained from Sigma Aldrich (Switzerland).

Compounds **1** and **2** were synthesized using the experimental procedures previously described [13,14]. Compound **3** was obtained from a 7-step synthesis from commercially available reagent **4** (Figure 2). Reaction of **4** with trichloroacetyl isocyanate in THF, followed by bromination gave compound **5** in 91% yield. Subsequent treatment with ammonia in methanol afforded intermediate **6**, which cyclized under basic conditions. Subsequent chlorination with POCl₃ gave key dichloro intermediate **7**. Two consecutive N-substitution reactions with 3-dimethylaminopropylamine under basic conditions and methyl amine respectively gave intermediate **8**, which underwent a final Suzuki cross-coupling reaction with phenylboronic acid to give the desired compound **3** as a white solid (Gonzalez Cabrera D *et al.*: 2,4-Diamino-thienopyrimidines as orally active anti-malarial agents. Manuscript submitted). All three compounds were analysed by HPLC prior to biological experiments and were found to be >98% pure.

[3 H]hypoxanthine was purchased from ANAWA Trading SA (Wangen, Switzerland). Anti-malarial compounds were dissolved in DMSO at 10 mg/mL. The stock solutions were kept at 4°C for not more than six months. Dilutions were prepared from stock solution immediately before use. The DMSO concentration (<0.5%) in the experiments had no inhibitory effect on parasite cultures.

Parasite cultivation

The drug-sensitive *Plasmodium falciparum* strain NF54 (airport strain from the Netherlands) was provided by F Hoffmann-La Roche Ltd (Basel, Switzerland). The parasites




Figure 1 Structures of compounds **1**, **2** and **3**.




Figure 2 Synthetic route for compound 3. Reagents and Conditions: (i) trichloroacetyl isocyanate (1 eq), THF, 0°C to r.t., 2 h, 91%; (ii) bromine (3.8 eq), acetic acid, 0°C to 80°C, 14 h, 65%; (iii) ammonia, CH₃OH, 0°C to r.t., 30 min, 76%; (iv) *t*-BuOK, DMF, RT, 14 h, 99%; (v) POCl₃, *N,N*-dimethyl aniline (0.5 eq), 130°C, 14 h 88%; (vi) 3-dimethylaminopropylamine (1 eq), Na₂CO₃ (2 eq), EtOH, r.t., 14 h, 72%; (vii) 2 M methyl amine in THF (10 eq), dioxane, sealed tube, 100°C, 14 h, 83%; (viii) phenylboronic acid (1.1 eq), Pd(PPh₃)₂Cl₂ (0.05 eq), aq. 1 M K₂CO₃ (1.05 eq), DMF, 90°C, 14 h, 63%.

were cultivated at 37°C as has been described [16]. Briefly, the medium consisted of RPMI 1640 supplemented with 0.5% ALBUMAX II, 25 mM Hepes, 25 mM NaHCO₃ (pH 7.3), 0.36 mM hypoxanthine, and 100 g/ml neomycin. Human erythrocytes served as host cells. Cultures were maintained at 37°C in an atmosphere of 3% O₂, 4% CO₂, and 93% N₂ in humidified modular chambers.

IC₅₀ speed assay

A schematic representation of the IC₅₀ speed assay is shown in Figure 3. Briefly, parasite growth in the presence of anti-malarial compounds was assessed using the [³H]hypoxanthine incorporation assay and expressed as IC₅₀ values [17]. For each compound, three incubation times were employed: 72 (standard assay time), 48 and




Figure 3 Schematic representation of the two *in vitro* assays. The "IC₅₀ speed assay" and "stage-specificity analysis" are performed with unsynchronized and synchronized parasite cultures, respectively. R, rings; S, schizonts.

24 hours. In the case of the 72- and 48-hour assays, radioactive hypoxanthine was added for the last 24 hours. In the case of the 24-hour assay, [³H]hypoxanthine was added during the last eight hours. IC₅₀ values in the standard 72-hour assay for chloroquine, artesunate, atovaquone, pyrimethamine, **1**, **2** and **3** were previously found to be 5.1 ± 0.8 [14], 1.6 ± 0.1 [14], 0.38 ± 0.04 [18], 5.6 ± 0.5 [18], 18 ± 1 [13], 26 ± 4 [14] and 9.5 ± 2.6 [16] ng/mL.

Stage-specificity analysis

Using synchronized cultures of NF54, the concentration-dependent growth of ring and schizont forms in the presence of anti-malarial compounds was measured as previously described [18].

As depicted in Figure 3, NF54 cultures were synchronized twice with 5% D-sorbitol. To obtain early schizont stages, the second sorbitol treatment was done six to eight hours after the first. This procedure provided initially a parasite culture containing ≥80% young trophozoites (up to 20 hours old), which after cultivation of another 16 hours resulted in early schizont stages (up to 36 hours old).

To obtain ring forms, the second sorbitol treatment was performed 31 hours after the first, yielding a parasite culture with ≥80% rings (up to three hours old).

One 96-well microtitre plate for each of the two synchronous stages was then incubated for 24 hours with two-fold serial dilutions of anti-malarial compounds. Investigated concentrations ranged from 1.6-100 × the previously determined IC₅₀ of each compound in a standard 72-hour assay. Following incubation, the plates were washed 4x resulting in a >1,000-fold dilution of free compound followed by another incubation period of 24 hours at 37°C in the presence of [³H]hypoxanthine. The plates were then frozen at -20°C or directly processed as described [17].

Results

The herein described methodology consists of two independent experimental approaches. The first assay was named "IC₅₀ speed assay" and is performed with unsynchronized cultures, and the second one "stage specificity analysis" (Figure 3).

In the IC₅₀ speed assay, IC₅₀ values were determined side-by-side for the four anti-malarial standards chloroquine, artesunate, atovaquone, and pyrimethamine as well as the three novel compounds **1**, **2** and **3** (Figure 1) after total incubation times of unsynchronized parasite cultures for 24, 48 and 72 hours (Figure 4, Additional file 1: Table S1). The 24-hours assay with chloroquine, artesunate, **2** or **3** resulted in very similar IC₅₀ values compared to the standard 72-hour assay (ratio of IC₅₀ 24 hours/IC₅₀ 72 hours was 1.1, 1.1, 1.6 and 1.2). The IC₅₀s of atovaquone, pyrimethamine and **1** were 3.6-, 8.3- and 4.3-fold higher at the 24-hour time point




Figure 4 IC₅₀ speed assay (NF54 unsynchronized culture; mean ± SD of n = ≥3 independent assays). CHQ, chloroquine; ART, artemisinin; ATO, atovaquone; PYR, pyrimethamine.

compared to the those generated at the 72-hour time point (Figure 4, Additional file 1: Table S1). These data, obtained after three working days, constituted the first indication that the latter compounds were not fast-acting molecules (Table 1).

The stage-specificity assay was performed with either young rings or young schizonts, which were incubated for 24 hours with serial dilutions (concentrations ranging from 1.6-100× of the previously determined IC₅₀ values) of the above-mentioned seven anti-malarial compounds. Subsequently free compounds were removed and plates again incubated in the presence of radioactive hypoxanthine for 24 hours. Initial results from this test can be obtained within four working days.

The rationale to perform the stage-specificity assay was to challenge the data from the IC₅₀ speed assay. Assuming, for instance, that the IC₅₀ speed assay would categorize a compound as non-fast-acting, and the stage-specificity assay would indicate a preferred action on young schizonts, then the latter data could provide an explanation as to why a compound is acting slowly. A comparable scenario turned out to be the case for pyrimethamine. The above mentioned 8.3-fold IC₅₀ 24 hour/IC₅₀ 72 hour shift in the IC₅₀ speed assay (Figure 4) could be explained by the minor activity against rings (Figure 5). The observation that pyrimethamine acts only on older forms (Figure 5) is not unexpected, since similar data have been published previously [19].

Atovaquone data from the IC₅₀ speed assay suggests that this drug has a slow action. This was also supported by the data from the stage-specificity assay, showing not more than 70 and 90% action against rings and schizonts (Figure 5). Those observations are in line with recent reports from 2 groups [20,21], who indicate that atovaquone has weak inhibitory activity against the rings and schizonts for the lines tested.

It is likely that the inhibitory effect of compounds acting even slower than atovaquone or pyrimethamine would be poorly represented in the here described methodology,

Table 1 Data overview of IC50 speed assay and stage specificity analysis

Compound	Assay 1 (A1): IC50 speed assay (ratio of IC50 24 h/IC50 72 h) ^a	Conclusion A1	Assay 2 (A2): Stage specificity analysis (at 6-100x IC50)	Conclusion A2	Concluded speed of action
Chloroquine	1.1	Fast	>95% action on R ^b >95% action on S ^b	Fast (cidal)	Fast (cidal)
Artesunate	1.1	Fast	>95% action on R >95% action on S	Fast (cidal)	Fast (cidal)
Atovaquone	3.6	Not fast	~50-70% action on R ~75-90% action on S	Not fast (cidal)	Not fast (cidal)
Pyrimethamine	8.3	Not fast	~5% action on R ~90% action on S	Not fast (cidal)	Not fast (cidal)
1	4.3	Not fast	~0-75% action on R >95% action on S	Not fast (cidal)	Not fast (cidal)
2	1.6	Fast/Not fast	~40- >95% action on R >95% action on S	Not fast (cidal)	Not fast
3	1.2	Fast	>95% action on R >95% action on S	Fast (cidal)	Fast (cidal)

^aRatios are means from ≥ 3 independent experiments performed with *P. falciparum* strain NF54.

^bR and S are abbreviations for the ring and schizont stages, respectively.




Figure 5 Stage-dependent effects of chloroquine, artesunate, atovaquone, pyrimethamine and compounds 1, 2 and 3 on synchronous cultures of *Plasmodium falciparum* strain NF54. Cultures were exposed to 7 different concentrations of the compound for 24 h. After removal of the compounds, parasites were incubated for another 24 h in the presence of [³H]hypoxanthine. Compound effects are expressed as the percentage of growth of the respective development stage relative to an untreated control. The open bar is the ring stage and the filled bar is the schizont stage. Each bar represents the mean ± SD of n = ≥ 3 independent experiments. CHQ, chloroquine; ART, artesunate; ATO, atovaquone; PYR, pyrimethamine.

since the maximum drug incubation time is 72 h. For instance in the case of azithromycin, a drug with a so-called delayed death phenotype above 72 h, it has been described previously that significant parasite growth reduction can only be observed by extending the drug exposure time to at least 96 h [12,22]. The prolongation of the total incubation times of the here described assays should help to address this fact.

Chloroquine and artesunate were found to be fast-acting compounds (Figure 4) and showed similar activity against rings and schizonts (Figure 5). These observations fit with what is known from the literature about those compounds [12,18,23].

Similarly, in the case of two of the three novel compounds, there was a good match between the two assays. Compound 1 showed a similar stage-specific profile like pyrimethamine, with predominantly strong action against young schizonts. The activity against young ring forms was <20% at concentrations up to 13× the IC₅₀ and only ~60-75% in the higher concentration range. Compound 3 showed high activity against both blood stages (>95% on rings and schizonts in the 6-100× IC₅₀ range), which suggests it is a fast-acting compound, similarly to what the IC₅₀ speed assay had already demonstrated.

The only molecule showing contradictory results between the assays was compound 2. The data from the IC₅₀ speed assay suggests a relatively fast action (1.6-fold IC₅₀ 24 hour/IC₅₀ 72 hour shift). However, the stage-specificity assay proposes a slow action on rings (~40-60% activity at concentrations up to 13× the IC₅₀ and >95% activity only at the two highest concentrations). Theoretically it should indeed be possible to see different outcomes, e.g., it can be expected that due to the constant presence of compound during the assay incubation time of the IC₅₀ speed assay, the latter would likely not be the right assay to detect if a compound is acting in a static or a cidal manner, because a viable but metabolically inactive parasite would be measured as dead. The stage-specificity assay, however, should have the potential to discriminate between static and cidal compounds, because of the washing procedure implemented after the compound incubation period. The washing is expected to remove the compound during the time when the metabolic activity is being determined. Since the data from both assays were in agreement in the case of all compounds except for molecule 2, it can be expected that they should have cidal activities (Table 1).

The lack of correlation between the two assays in the case of compound 2 suggests that performing only one of them might not be acceptable. An exception could be anti-malarial compounds with certain defined phenotypes. There the assays could be interchangeable. However, in the absence of such knowledge, and until the

assays are further validated with compounds of more chemical diversity, we do not recommend this approach.

Conclusions

The results obtained for the anti-malarials chloroquine, artesunate, atovaquone, and pyrimethamine are consistent with previous observations [12,18-21,23]. This suggests that the assays described here are valid to rapidly discriminate between fast- and slow-acting anti-malarial compounds, providing valuable information to guide and accelerate the development of new classes of anti-malarial compounds.

Additional file

Additional file 1: Table S1. IC₅₀s (ng/ml) of all speed assays (NF54 unsynchronized culture).

Abbreviations

PRR: Parasite reduction ratio; ACT: Artemisinin-based combination therapy; CHQ: Chloroquine; ART: Artemisinin; ATO: Atovaquone; PYR: Pyrimethamine.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CLM, CSC, XDI, DLE and SWI designed research. CSC, SSA and SSC performed research. All authors analysed data. All authors from UCT contributed to reagents. CLM and SW wrote the manuscript. All authors had full access to all data in the study and read and approved the final manuscript.

Acknowledgements

We would like to thank Hugues Matile, Matthias Rottmann, Jonathan L Vennerstrom, Laura Maria Sanz-Alonso and Francisco Javier Gamo-Benito for their helpful comments to various versions of this document. This work was supported in part by Medicines for Malaria Venture (www.mmv.org).

Author details

¹Department of Chemistry, University of Cape Town, Rondebosch, 7701, South Africa. ²Parasite Chemotherapy Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland. ³University of Basel, Basel CH-4003, Switzerland. ⁴Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa. ⁵Medicines for Malaria Venture, ICC, 20 Route de Pré-Bois, PO Box 1826, Geneva 1215, Switzerland.

Received: 17 September 2013 Accepted: 13 November 2013

Published: 16 November 2013

References

1. World Health Organization: *World Malaria Report 2012*. Geneva, Switzerland: World Health Organization; 2012. http://www.who.int/malaria/publications/world_malaria_report_2012/en/.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Arie F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: **Artemisinin resistance in Plasmodium falciparum malaria.** *N Engl J Med* 2009, **361**:455-467.
3. Phyto AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: **Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study.** *Lancet* 2012, **379**:1960-1966.
4. Fidock DA: **Priming the antimalarial pipeline.** *Nature* 2010, **465**:297-298.
5. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DVS, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF: **Thousands of chemical starting points for antimalarial lead identification.** *Nature* 2010, **465**:305-310.

6. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA: **In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.** *Proc Natl Acad Sci U S A* 2008, **105**:9059–9064.
7. Guiguenne WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jiménez-Díaz MB, Martínez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, DeRisi JL, Sullivan DJ Jr, Lazo JS, Roos DS, Riscoe MK, *et al*: **Chemical genetics of *Plasmodium falciparum*.** *Nature* 2010, **465**:311–315.
8. Wells TNC, Alonso PL, Gutteridge WE: **New medicines to improve control and contribute to the eradication of malaria.** *Nat Rev* 2009, **8**:879–891.
9. Burrows JN, Leroy D, Lotharius J, Waterson D: **Challenges in antimalarial drug discovery.** *Future Med Chem* 2011, **3**:1401–1412.
10. Biamonte MA, Wanner J, Le Roch KG: **Recent advance in malaria drug discovery.** *Bioorg Med Chem Lett* 2013, **23**:2829–2843.
11. Burrows JN, Hooft van Huijsduijnen R, Möhrle JJ, Oeuvray C, Wells TN: **Designing the next generation of medicines for malaria control and eradication.** *Malar J* 2013, **12**:187.
12. Sanz LM, Crespo B, De-Cozar C, Ding XC, Llergo JL, Burrows JN, García-Bustos JF, Gamó F-J: ***P. falciparum* in vitro killing rates allow to discriminate between different antimalarial mode-of-action.** *PLoS One* 2012, **7**:e30949.
13. Younis Y, Douelle F, Feng T-S, González Cabrera D, Le Manach C, Nchinda AT, Duffy S, White KL, Shackleford DM, Morizzi J, Mannila J, Katneni K, Bhamidipati R, Zabiulla KM, Joseph JT, Bashyam S, Waterson D, Witty MJ, Hardick D, Wittlin S, Avery VM, Charman SA, Chibale K: **3,5-diaryl-2-aminopyridines as a novel class of orally active antimalarial demonstrating single doses cure in mice and clinical candidate potential.** *J Med Chem* 2012, **55**:3479–3487.
14. González Cabrera D, Douelle F, Feng T-S, Nchinda AT, Younis Y, White LK, Wu Q, Ryan E, Burrows JN, Waterson D, Witty MJ, Wittlin S, Charman SA, Chibale K: **Novel orally active antimalarial thiazoles.** *J Med Chem* 2011, **54**:7713–7719.
15. Harris JC, Hill DR, Sheppard WD, Slater JM, Stouten WFP: **The design and application of target-focused compound libraries.** *Comb Chem High Throughput Screening* 2011, **14**:521–531.
16. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193**:673–675.
17. Snyder C, Chollet J, Santo-Tomas J, Scheurer C, Wittlin S: **In vitro and in vivo interaction of synthetic peroxides RBx11160 (OZ277) with piperazine in *Plasmodium* models.** *Exp Parasitol* 2007, **115**:296–300.
18. Hofer S, Brun R, Maerki S, Scheurer C, Wittlin S: **In vitro assessment of the pharmacodynamic properties of DB75, piperazine, OZ277 and OZ401 in cultures of *Plasmodium falciparum*.** *J Antimicrob Chemother* 2008, **62**:1061–1064.
19. Dieckmann A, Jung AZ: **Stage specificity of *Plasmodium falciparum* to antifolates.** *Parasitenkd* 1986, **72**:591–594.
20. Wilson DW, Langer C, Goodman CD, McFadden GI, Beeson JG: **Mechanisms of action: defining the timing of action of antimalarial drugs against *Plasmodium falciparum*.** *Antimicrob Agents Chemother* 2013, **57**:1455–1467.
21. Painter HJ, Morrissey JM, Vaidya AB: **Mechanisms of action: physiological effects. Mitochondrial electron transport inhibition and viability of intraerythrocytic *Plasmodium falciparum*.** *Antimicrob Agents Chemother* 2010, **54**:5281–5287.
22. Dahl EL, Rosenthal PJ: **Multiple antibiotics exert delayed effects against the *Plasmodium falciparum* apicoplast.** *Antimicrob Agents Chemother* 2007, **51**:3485–3490.
23. Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S: **In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of *Plasmodium falciparum*.** *J Antimicrob Chemother* 2006, **58**:52–58.

doi:10.1186/1475-2875-12-424

Cite this article as: Le Manach *et al.*: Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in *Plasmodium falciparum*. *Malaria Journal* 2013 **12**:424.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

